Is Nimodipine registered with the SFDA?

The SFDA human drug list (edition 4-2026, as published by the Council of Health Insurance) lists 2 valid registrations of Nimodipine, including NIMOTOP 10MG-50ML Infusion (0.2 mg/ml, Solution for infusion, SAR 41.15); NIMOTOP 30MG TAB (30 mg, Tablet, SAR 46.50).

Is Nimodipine approved by the US FDA?

Drugs@FDA lists 10 application product lines for Nimodipine, including NIMODIPINE (Prescription); NIMODIPINE (Prescription); NYMALIZE (Prescription); NIMODIPINE (Prescription); NIMODIPINE (Prescription).

Are there safety signals or safety updates for Nimodipine?

US FDA: 1 entry (latest 2019-12-28).

Active substance

Nimodipine

SFDA 2
US FDA 10
Health Canada 1
US price lines 1
NHS prices 1
Safety 1

Open in the medicines table

SFDA Saudi Arabia — SFDA human drug list

Trade name	Strength	Form · route	Pack	Public price	Type	Company	Status
NIMOTOP 10MG-50ML Infusion	0.2 mg/ml	Solution for infusion · Intravenous use	1 Bottle	SAR 41.15	NCE · Prescription	BAYER PHARMA AG	Valid
NIMOTOP 30MG TAB	30 mg	Tablet · Oral use	30 Blister	SAR 46.50	NCE · Prescription	BAYER AG	Valid

Indications — CHI Daman Drug Formulary

SYSTEMIC LUPUS ERYTHEMATOSUS

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
NIMODIPINE	30MG	capsule · oral	HERITAGE	Prescription	2 May 2007
NIMODIPINE	30MG	capsule · oral	BIONPHARMA	Prescription	17 Jan 2008
NYMALIZE	6MG/ML	solution · oral	AZURITY	Prescription	10 May 2013
NIMODIPINE	30MG	capsule · oral	THEPHARMANETWORK LLC	Prescription	7 Apr 2014
NIMODIPINE	3MG/ML	solution · oral	ANNORA PHARMA	Prescription	9 Jul 2024
NIMODIPINE	6MG/ML	solution · oral	ALKEM LABS LTD	Prescription	22 Jan 2025
NIMOTOP	30MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	capsule · oral	BAYER PHARMS	Discontinued	28 Dec 1988
NIMODIPINE	30MG	capsule · oral	SUN PHARM INDS INC	Discontinued	17 Apr 2007
NYMALIZE	3MG/ML Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	solution · oral	AZURITY	Discontinued	10 May 2013
NIMODIPINE	30MG	capsule · oral	SOFGEN PHARMS	Discontinued	24 Jul 2015

Canada Canada — marketed products (Health Canada)

Brand	DIN	Strength	Form · route	Company
NIMOTOP	02325926	30 MG	TABLET · ORAL	LABORATOIRE X.0

Prices — United States and England

Source	Product as listed	Price	Unit / pack	Date
US NADAC	NIMODIPINE 30 MG CAPSULE	$1.36945	per EA	23 Sep 2026
NHS Drug Tariff	Nimodipine 30mg tablets	£40.00	100 tablet	1 Oct 2026

NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.

Safety signals and safety-related labeling changes

US FDA 28 Dec 2019 NYMALIZE — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide

All safety entries for nimodipine →

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.